Chemotherapy in head and neck cancer.

摘要: The role of chemotherapy in the management patients with head and neck cancer continues to evolve. Single-agent methotrexate or cisplatin, combination cisplatin infusional fluorouracil can be considered standard therapy for recurrent disease. Neoadjuvant is being actively pursued. Although enhanced survival has not yet been demonstrated, goal organ preservation achieved laryngeal cancer. Because high incidence locoregional failure, concomitant chemoradiotherapy also under investigation. This treatment approach already suggested result prolonged randomized studies holds promise future.